German medtech startup Sedivention has successfully closed a €2.9 million seed funding round to advance its innovative obesity treatment. The financing, led by bmp Ventures and the IBG funds, will support the development of a minimally invasive, one-time therapy. This new approach aims to provide a compelling alternative to lifelong medications and invasive bariatric surgery for a growing global population.
A New Approach to a Global Health Crisis
Obesity represents one of the most significant medical and economic challenges today, with projections indicating over one billion people will be affected by 2030. Current treatments have considerable drawbacks, as bariatric surgery is highly invasive and accessible to few, while popular weight-loss drugs are expensive and require lifelong use. Sedivention aims to fill this critical gap with a more accessible and sustainable solution for patients.
Pioneering Vagus Nerve Cryoablation
Sedivention is developing a unique therapy centered on a specially designed cryo balloon catheter. The device is inserted non-surgically in a procedure similar to a gastroscopy to deliver targeted cold energy, a process known as cryoablation. This single outpatient session is designed to interrupt the hunger-related branches of the vagus nerve without leaving any implants in the body.
This innovative procedure directly addresses the physiological root of chronic overeating by resetting the brain signals that regulate hunger and satiety. By interrupting these nerve pathways, the treatment aims to achieve a lasting reduction in feelings of hunger. The goal is to offer a permanent solution without altering the body's anatomy or requiring continuous medical intervention.
Strategic Investment for Market Entry
The €2.9 million investment round saw participation from High-Tech Gründerfonds, superangels, Cambridge Ventures, and the strategic arm of an unnamed global medtech firm. This capital infusion is earmarked for completing product development and gathering initial clinical data. These steps are crucial for preparing the technology for market entry and subsequent regulatory approvals.
The company is targeting a massive global market, with healthcare costs related to obesity projected to reach $4 trillion annually. Co-founder and CEO Dr. Andreas Bröcker stated that the proprietary solution has the potential to redefine a multi-billion dollar market. The technology was designed for international scalability from its inception to tap into this significant growth potential.
A Competitive Edge in Obesity Treatment
While established companies like Medtronic and ReShape Lifesciences are exploring neuromodulation for obesity, their methods often involve permanent implants requiring ongoing stimulation. Sedivention distinguishes itself by using ablation, offering a single treatment that avoids the complications and long-term management of implanted devices. This provides a clear advantage in terms of patient convenience and cost-effectiveness.
Investors have expressed strong confidence in the startup's vision and technological platform. Dr. Jan Engels of HTGF highlighted the combination of medical evidence with a scalable and cost-effective medtech approach. This sentiment underscores the belief that Sedivention is providing a technologically compelling solution to a globally relevant medical condition.
With this new funding, Sedivention is poised to advance its mission of transforming obesity care. The company's long-term goal is to replace highly invasive surgical procedures with scalable, interventional treatments that can be performed on an outpatient basis. This development marks a significant step toward improving access to effective medical care for millions of people worldwide.